Targeting Epstein–Barr virus is a viable therapeutic strategy in multiple sclerosis: Yes
- 14 January 2026
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (4) , 359-360
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controlsProceedings of the National Academy of Sciences, 2025
- Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic ApproachCNS Drugs, 2025
- Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosisScience Advances, 2023
- Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trialsClinical & Translational Immunology, 2023
- Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAMNature, 2022
- Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosisScience, 2022
- Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis riskProceedings of the National Academy of Sciences, 2019
- The Discovery of Oligoclonal Bands: A 50-Year AnniversaryEuropean Neurology, 2009